Background: Various therapeutical approaches for wart are possible, depending on age, sex, immune status, extension of the body and severity of lesion. .Recently intralesional immunotherapy by MMR vaccine has shown good effect among the nondestructive treatment. Two MMR vaccines, M-M-R II® (Merck & Co.) and Priorix® (GlaxoSmithKline) have been used for vaccination in Korea. However, the two vaccines contain different strains, and Priorix was developed more recently. Objectives: This study is to compare the effect of intralesional immunotherapy using M-M-R II® and Priorix® Methods: A retrospective study was performed, and we enrolled 380 patients with various types of warts into the study, which was for a duration of 6 years. Depending on the decrease in wart size, response to treatment was classified into three categories; CR(100%), partial response (PR)(50-99%) and no response (NR) (<50%). Patients were treated for at least three times every two weeks from injection therapy was performed up to five times. Results: Over half (64.25%) of patients experienced > 50% reduction in the size and number of warts treated with Priorix®. On the other intralesional immunotherapy using M-M-R II® was less than half (45.66%). Conclusion: We suggest that intralesional immunotherapy with Priorix® more effective than using M-M-R II®. This is thought to be due to antigenic polymporphisms in each vaccine strain produce strain-specific immunity.